Marketing-authorisation holder · United States
Acrotech Biopharma Inc.
7 medicines in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
7 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ADQUEY1% · Ointment | Difamilast | United States | Marketed | 2026 |
| BELEODAQ500mg/vial · Powder | Belinostat | United States | Marketed | 2014 |
| EVOMELA50mg base/vial · Powder | Melphalan | United States | Marketed | 2016 |
| FOLOTYN20mg/ml (20mg/ml) | 40mg/2ml (20mg/ml) · Solution | Pralatrexate% | United States | Marketed | 2009 |
| FUSILEV175MG BASE/17.5ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 250MG BASE/25ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Levoleucovorin | United States | Not marketed | 2008 |
| FUSILEV50mg base/vial · Powder | Levoleucovorin | United States | Not marketed | 2008 |
| KHAPZORY175mg/vial | 300mg/vial · Powder | Levoleucovorin | United States | Marketed | 2018 |
Countries
Where it holds or makes medicines, with how many are current.